News

Galderma’s Differin gel 0.1% will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi. Approval was based on non-clinical

The transaction is expected to be modestly accretive to Omnicare’s earnings in 2008, with accretion expected to increase in 2009 and beyond. Joel Gemunder, president and CEO of

Immunosyn is negotiating an exclusive license agreement for the administration and distribution of SF-1019 in the State of Utah with Utah Biopharmaceutical Laboratories. Immunosyn has been advised by

In addition to serving the Middle East and North African (MENA) countries with marketing and distribution of company owned and developed products, Generex MENA also identifies other complimentary

According to Iris, iQ200 uses Auto-Particle Recognition, a well-trained neural network, to classify and quantitate 12 formed elements with true image morphology and walkway capability, providing the highest

Up to 55 RhD-positive adult non-splenectomized patients with idiopathic thrombocytopenic purpura (ITP) will be enrolled in this first exploratory open label safety, efficacy and dose-finding trial. The study

The top-line analysis of data from this study shows that Prulifloxacin met the primary endpoint of time to last unformed stool (TLUS) in both the mITT (modified intent-to-treat;

Under the agreement, EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-investigational new drug (IND)

Under the terms of the agreement, Theragenics will pay $47.8 million in cash, plus transaction costs, for NeedleTech, subject to the terms and conditions of the agreement. Theragenics